Literature DB >> 32687727

The m6A methylation regulator-based signature for predicting the prognosis of prostate cancer.

Jiamin Wang1, Han Lin2, Mingda Zhou1, Qian Xiang1, Yihan Deng1, Lianmin Luo1, Yangzhou Liu1, Zhiguo Zhu1, Zhigang Zhao1.   

Abstract

Aim: To construct a survival prediction signature for prostate cancer (PC) based on the RNA N6-methyladenosine (m6A) methylation regulator. Materials & methods: This paper explores the interaction network of differentially expressed m6A RNA methylation regulators in PC by Pearson correlation analysis. Univariate Cox risk regression and LASSO regression analysis were used to construct a predictive signature of PC. Kaplan-Meier survival analysis compared the overall survival of the high- and low-risk groups. Results &
Conclusion: We first constructed a prognostic two gene signature for PC based on the m6A RNA methylation regulators MRTTL14 and YTHDF2. The interaction network of m6A RNA methylation regulators in PC was also established.

Entities:  

Keywords:  TCGA; bioinformatics; m6A RNA methylation regulator; prostate cancer; signature; survival

Mesh:

Substances:

Year:  2020        PMID: 32687727     DOI: 10.2217/fon-2020-0330

Source DB:  PubMed          Journal:  Future Oncol        ISSN: 1479-6694            Impact factor:   3.404


  10 in total

1.  Molecular Characterization and Clinical Relevance of N6-Methyladenosine Regulators in Metastatic Prostate Cancer.

Authors:  Qiwei Liu; Zhen Li; Lizhao He; Ke Li; Chen Hu; Jialiang Chen; Fangjian Zhou; Jun Wang; Yonghong Li; Hengjun Xiao
Journal:  Front Oncol       Date:  2022-06-22       Impact factor: 5.738

Review 2.  RNA m6A Modification in Cancers: Molecular Mechanisms and Potential Clinical Applications.

Authors:  Chang Gu; Xin Shi; Chenyang Dai; Feng Shen; Gaetano Rocco; Jiafei Chen; Zhengyu Huang; Chunji Chen; Chuan He; Tao Huang; Chang Chen
Journal:  Innovation (Camb)       Date:  2020-11-04

3.  Identification of an Immune-Related Gene Signature to Improve Prognosis Prediction in Colorectal Cancer Patients.

Authors:  Siqi Dai; Shuang Xu; Yao Ye; Kefeng Ding
Journal:  Front Genet       Date:  2020-12-04       Impact factor: 4.599

4.  RNA m6A Methylation Regulators Multi-Omics Analysis in Prostate Cancer.

Authors:  Hao Su; Yutao Wang; Hongjun Li
Journal:  Front Genet       Date:  2021-11-26       Impact factor: 4.599

5.  Comprehensive Landscape of HOXA2, HOXA9, and HOXA10 as Potential Biomarkers for Predicting Progression and Prognosis in Prostate Cancer.

Authors:  Yan-Ping Song; Peng Xian; Hong Luo; Jun-Yong Dai; Yu Bai; Yuan Li; Xian-Li Tang
Journal:  J Immunol Res       Date:  2022-03-24       Impact factor: 4.818

6.  Construction of a Comprehensive Diagnostic Scoring Model for Prostate Cancer Based on a Novel Six-Gene Panel.

Authors:  Yunfeng Liu; Simei Qiu; Dongshan Sun; Ting Xiong; Qiuling Xiang; Quhuan Li
Journal:  Front Genet       Date:  2022-04-26       Impact factor: 4.772

7.  Methyltransferase-like 3 induces the development of cervical cancer by enhancing insulin-like growth factor 2 mRNA-binding proteins 3-mediated apoptotic chromatin condensation inducer 1 mRNA stability.

Authors:  Cuihong Su; Yan Zhang; Ping Chen; Wei Yang; Jiaqiu Du; Danfeng Zhang
Journal:  Bioengineered       Date:  2022-03       Impact factor: 6.832

8.  m6A Methylation Regulators Are Predictive Biomarkers for Tumour Metastasis in Prostate Cancer.

Authors:  Yingchun Liang; Xiaohua Zhang; Chenkai Ma; Jimeng Hu
Journal:  Cancers (Basel)       Date:  2022-08-21       Impact factor: 6.575

Review 9.  Functions and mechanisms of N6‑methyladenosine in prostate cancer (Review).

Authors:  Hongyuan Wan; Yanyan Feng; Junjie Wu; Lijie Zhu; Yuanyuan Mi
Journal:  Mol Med Rep       Date:  2022-07-20       Impact factor: 3.423

10.  Construction of a risk prediction model using m6A RNA methylation regulators in prostate cancer: comprehensive bioinformatic analysis and histological validation.

Authors:  Yongjun Quan; Xiaodong Zhang; Hao Ping
Journal:  Cancer Cell Int       Date:  2022-01-19       Impact factor: 5.722

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.